A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

NCT00159653 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Open-Angle
Ocular Hypertension

Interventions

DRUG: Xalacom
DRUG: Xalatan
DRUG: Timolol

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.